SG&A Efficiency Analysis: Comparing Walgreens Boots Alliance, Inc. and Rhythm Pharmaceuticals, Inc.

SG&A Efficiency: A Tale of Two Companies

In the world of corporate finance, Selling, General, and Administrative (SG&A) expenses are a critical measure of operational efficiency. This analysis juxtaposes the SG&A expenses of Walgreens Boots Alliance, Inc. and Rhythm Pharmaceuticals, Inc. over a decade, from 2014 to 2023.

Walgreens Boots Alliance, Inc.

Walgreens, a retail giant, consistently reported SG&A expenses in the range of $17.7 billion to $28.1 billion annually. Despite fluctuations, the company maintained a steady increase, peaking in 2024. This trend reflects Walgreens' expansive operations and strategic investments in global markets.

Rhythm Pharmaceuticals, Inc.

In contrast, Rhythm Pharmaceuticals, a smaller biotech firm, exhibited a dramatic rise in SG&A expenses, from $1.2 million in 2014 to $117.5 million in 2023. This 9,600% increase underscores the company's aggressive growth strategy and investment in research and development.

The data reveals a stark contrast in scale and strategy between these two companies, offering valuable insights into their operational priorities.